IDT Australia Limited
IDT Australia Limited
Your view on IDT.AX
Overview
What the company does, where it operates, and who runs it.
About IDT Australia Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mark Simari
- Headquarters
- 45 Wadhurst Drive, Boronia, VIC, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mark Simari
- Headquarters
- 45 Wadhurst Drive, Boronia, VIC, AU
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for IDT Australia Limited, and the rating behind it. IDT.AX last traded at AUD 0.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for IDT Australia Limited. Starting points for IDT Australia Limited: EPS -AUD 0.01, beta 0.94 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for IDT Australia Limited. IDT Australia Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for IDT Australia Limited. Trailing twelve-month EPS for IDT Australia Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for IDT Australia Limited. IDT Australia Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
IDT Australia Limited valued side by side against its closest peers. IDT Australia Limited is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold IDT Australia Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by IDT Australia Limited executives and directors. Shares of IDT Australia Limited have traded between AUD 0.03 and AUD 0.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming IDT Australia Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming IDT Australia Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for IDT Australia Limited. Coverage tracks IDT Australia Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.